Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3103)	12/7/2010 10:58:24 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

CYTX was up 10.57% but is up only 4.81% with volume about 100Ks > its ADV. The stock is up for 3rd day on a roll.<g> bigcharts.marketwatch.com CYTX announced that it had entered into an agreement with Japan's Astellas Pharma to evaluate the potential of adipose derived stem cells for the treatment of serious illnesses for which there is no fundamental treatment. <g> Astellas will purchase approximately 1.43M unregistered shares of CYTX common $7.00 and CYTX granted Astellas some 'rights'.<g> Astellas will have a two year right of first refusal to develop or commercialize CYTX's products for the treatment of liver disease and also will have a non-voting "observer" seat on CYTX's board and serve on its newly-created scientific advisory board. The deal is expected to close around Dec. 13. As mentioned. the ACTAY is $9.50 and I will still keep a TT at $6 <g> bigcharts.marketwatch.com Bernard